Takeda Pharmaceutical Co. Ltd. has reported the first Phase III data for the investigational uterine fibroid treatment relugolix in Japanese patients in a study that is seen as a bellwether for larger international studies being undertaken by licensee Myovant Sciences Ltd.
The US firm licensed rights to the product outside Japan and certain other Asian countries in June 2016 for use...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?